Listening to calls to revise its offer for diagnostic kit maker Qiagen (NYSE:QGEN) amid bullish pandemic-stoked demand, Thermo Fisher Scientific (NYSE:TMO) has increased its per-share cash bid 10% to €43 from €39.
The amended deal includes a reduction in the minimum acceptance threshold to 66.67% of QGEN’s share capital from 75.00%.
QGEN’s board unanimously backs the amended agreement.
The acceptance period has been extended to August 10.
QGEN up 3% premarket.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.